Universidad de Granada Digibug
 

Repositorio Institucional de la Universidad de Granada >
1.-Investigación >
Proyectos Fin de Máster >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/33493

Title: Presentación de un proyecto de investigación: Prevención y tratamiento con fesoterodina de la toxicidad urinaria en pacientes sometidos a radioterapia por cáncer de próstata localizado.
Other Titles: A research project: Fesoterodine in the prevention and treatment of urinary toxicity in patients undergoing radiotherapy for localized prostate cancer.
Authors: Martin Way, David Alejandro
Direction: Expósito Hernández, José
Vázquez Alonso, Fernando
Collaborator: Universidad de Granada. Departamento de Radiología y Medicina Física
Hospital Universitario Virgen de las Nieves
Issue Date: 28-Oct-2014
Abstract: Introduction: Radiation cystitis occurs in up to 20% of patients with localized prostate cancer undergoing radiotherapy. Among several lines of treatment, one of the newest and most promising is the instillation of intravesical hyaluronic acid. However, antimuscarinic drugs are commonly administered as symptomatic treatment in routine clinical practice, despite the absence of published data on their effectiveness in this application. Objectives: The aim of this prospective study is to determine whether fesoterodine can prevent or treat radiotherapy-induced genitourinary toxicity in patients with high or intermediate risk of prostate cancer and whether it improves their quality of life. Methods: Patients diagnosed at high or intermediate risk of prostate cancer showing urinary toxicity pre- and post-radiation treatment will be treated with fesoterodine, and their symptoms will be assessed at baseline, three months and one year after starting treatment. Exclusion criteria will be: residual urine over 150 ml, maximum flow lower than 10 ml/s or International Prostate Symptom Score below 8. Results: Data will be analyzed when a sample of 50 patients is reached. The results of our study will be compared with data in the literature on patients who have not received fesoterodine. Conclusions: The aim of this prospective study is to demonstrate the efficacy of fesoterodine to treat residual urinary symptoms in patients with localized prostate cancer after radiation treatment.
Sponsorship: Universidad de Granada. Departamento de Radiología y Medicina Física. Máster Universitario en Avances en Radiología diagnóstica y terapéutica y medicina física. Curso académico 2013-2014
Keywords: Radioterapia
Cáncer de próstata
Cistitis rádica
URI: http://hdl.handle.net/10481/33493
Rights : Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Appears in Collections:Proyectos Fin de Máster

Files in This Item:

File Description SizeFormat
David_Martin_TFM_definitivo (3).pdfTFM Fesoterodina cáncer próstata1.65 MBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada